Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Raghav Gulati takes a one-shot lead with an impressive five-under-par 67 on Day One of the Tommy Fleetwood Pathway Series at ...
February's Full Moon, or Snow Moon, is a potent time for aligning with your deepest desires. Engaging with its energy ...
The R&A has announced the qualification pathways for The 153rd Open at Royal Portrush, taking place July 13-20, 2025. The ...
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback